European Primary Care Cardiovascular Society

IL-6 inhibition in CKD for CV risk reduction

5' education - June 1, 2021 - Prof. Paul Ridker, MD
Experts in dialogue - LDL-c goal attainment in high risk patients

Statin-intolerant patients and lipid-lowering therapies

15' education - June 1, 2021 - Prof. Maciej Banach, MD, PhD and prof. Ulrich Laufs, MD, PhD
Experts in dialogue - LDL-c goal attainment in high risk patients

Current barriers and challenges in achieving LDL-c goals

15' education - June 1, 2021 - Prof. Lale Tokgözoğlu, MD and prof. Kausik Ray, MD - Online CME

Controversy on omega-3FAs trials

5' education - May 27, 2021 - Prof. Eileen Handberg, PhD

Proven safety with ARNI in MI patients, but no definite difference for primary endpoint

5' education - May 27, 2021 - Prof. Marc Pfeffer, MD, PhD

Clinical outcomes not different with 81 mg vs. 325 mg aspirin in established CVD

5' education - May 26, 2021 - William Schuyler Jones, MD
Experts in dialogue - LDL-c goal attainment in high risk patients

How are we doing: The gap between guideline LDL-c goals and current practice

15' education - May 11, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD
Experts in dialogue - LDL-c goal attainment in high risk patients

Benefit of LDL-c lowering: a proven case

15' education - May 4, 2021 - Prof. Kausik Ray, MD and prof. John Kastelein, MD, PhD

Comparison of low dose vs. high dose DOAC in patients with AF

3' education - Apr. 21, 2021 - Prof. Jan Steffel, MD

CV and renal benefit predicted by reduction in albuminuria in T2DM

10' education - Apr. 15, 2021 - Frederik Persson, MD

Weight loss induction by GLP-1RA in adults with overweight or obesity

10' education - Mar. 25, 2021 - Prof. Robert Kushner, MD

High incidence of thrombotic complications in first and second COVID-19 wave

5' education - Mar. 5, 2021 - Fleur Kaptein, MD

The future of CV medicine: anti-inflammation

10' education - Mar. 5, 2021 - Prof. Paul Ridker, MD

Treat also older adults to lower LDL-c

5' education - Jan. 19, 2021 - Prof. Børge Nordestgaard, MD

Majority side effects of statins also present with placebo

3' education - Dec. 3, 2020 - Prof. Darrel Francis, MD

Widespread atherosclerosis in Swedish population

3' education - Dec. 3, 2020 - Prof. Göran Bergström, MD, PhD

Potentially no contradiction between omega-3 fatty acids trials

3' education - Dec. 3, 2020 - Prof. Deepak Bhatt, MD

The therapeutic options in HFrEF patients

3' education - Dec. 3, 2020 - Prof. Marc Pfeffer, MD, PhD

Omega-3 carboxylic acid has no effect on MACE in high risk patients

3' education - Dec. 3, 2020 - Prof. Michael Lincoff, MD

A polypill with or without aspirin to reduce global CVD burden

3' education - Dec. 3, 2020 - Prof. Salim Yusuf, MD

Confirmation of previous findings by updated results of the SPRINT trial

Literature - June 15, 2021 - The SPRINT Research Group
Additional analyses of all events through the end of the intervention period and post-trial observational follow-up data showed reduction of MACE and all-cause death with SBP target <120 mmHg compared to SBP target <140 mmHg.

Additional analyses of all events through the end of the intervention period and post-trial observational follow-up data showed reduction of MACE and all-cause death with SBP target <120 mmHg compared to SBP target <140 mmHg. With poll.

Tailored medical therapy for HFrEF patients in consensus document of HFA of ESC

News - June 15, 2021

The Heart Failure Association of the European Society of Cardiology has published a consensus document with patient profiles that may be relevant for treatment implementation in HFrEF patients.

CHMP recommends EC-approval of SGLT2 inhibitor for patients with HFrEF

News - June 15, 2021

Following the results from the EMPEROR-Reduced trial, the CHMP has issued a recommendation for empagliflozin in patients with symptomatic chronic HFrEF with or without T2DM to reduce the combined risk of CV death or HF hospitalization.

European Kidney Disease Prevention Campaign: "Strong Kidneys"

News - June 8, 2021
The ERA-EDTA has launched the

The ERA-EDTA has launched the "Strong Kidneys" campaign to raise awareness about kidney disease and its prevention.

Gap between guidelines and clinical practice for LDL-c goals larger in East-Central Europe

News - June 3, 2021

EAS 2021 This DA VINCI subanalysis showed that the proportion of patients achieving their risk-based LDL-c goal using the 2016 and 2019 ESC/EAS guidelines in patients on lipid lowering therapy for primary and secondary care was lower in Central- and East- Europe than in North- or West-Europe.

Increased risk of MACE with higher DHA levels adjusted for EPA

News - June 1, 2021

ACC 2021 In patients undergoing coronary angiography in the INSPIRE registry, higher levels of EPA unadjusted and adjusted for DHA were associated with lower MACE and in contrast, higher DHA levels adjusted for EPA were associated with higher MACE.

New-onset AF reduced by nonsteroidal MRA in DKD patients

News - June 1, 2021

ACC 2021 Risk of new-onset AF was reduced by 29% in patients randomized to finerenone compared to placebo in a population of patients with T2DM and CKD.

P2Y12i monotherapy as maintenance therapy after PCI

News - June 1, 2021

ACC 2021 In patients who had used DAPT for 6-18 months after PCI with DES, clopidogrel monotherapy as chronic maintenance therapy for 2 years reduced ischemic and bleeding outcomes compared to aspirin monotherapy.

IL-6 inhibition in CKD for CV risk reduction

5' education - June 1, 2021 - Prof. Paul Ridker, MD
Prof. Ridker talks about anti-inflammatory therapies to prevent CVD: What is the right drug and what is the right target population?

ACC 2021 Prof. Ridker talks about anti-inflammatory therapies to prevent CVD: What is the right drug and what is the right target population?

Reduction of hsCRP with novel IL-6 inhibitor in CKD with elevated hsCRP

News - June 1, 2021

ACC 2021 The phase 2 RESCUE trial showed that the IL-6 inhibitor ziltivekimab largely reduced hsCRP and other biomarkers of inflammation and thrombosis in patients with CKD and ≥2 mg/L hsCRP.

Statin-intolerant patients and lipid-lowering therapies

15' education - June 1, 2021 - Prof. Maciej Banach, MD, PhD and prof. Ulrich Laufs, MD, PhD

Experts in dialogue In a video on management of statin-intolerant patients, the discussants state that we are in a good position in 2021 with new options of lipid-lowering therapies for these patients.

Current barriers and challenges in achieving LDL-c goals

15' education - June 1, 2021 - Prof. Lale Tokgözoğlu, MD and prof. Kausik Ray, MD - Online CME
Two lipid experts discuss what the possible barriers are for implementing guidelines and not reaching goals with regard to LDL-c and how to overcome these.

Experts in dialogue Two lipid experts discuss what the possible barriers are for implementing guidelines and not reaching goals with regard to LDL-c and how to overcome these barriers.

Agenda